Liraglutide and Cardiometabolic Effects: More than Just Another Antiobesity Drug?

被引：14
作者：
Katsiki, Niki [1 ]
Christou, Georgios A. [2 ]
Kiortsis, Dimitrios N. [2 ]
机构：
[1] Aristotle Univ Thessaloniki, Sch Med, Propedeut Dept Internal Med 2, GR-54006 Thessaloniki, Greece
[2] Univ Ioannina, Sch Med, Lab Physiol, GR-45110 Ioannina, Greece
来源：
CURRENT VASCULAR PHARMACOLOGY | 2016年 / 14卷 / 01期
关键词：
FATTY LIVER-DISEASE; LIPOPROTEIN LDL SUBCLASSES; CHRONIC KIDNEY-DISEASE; CLINICAL-SIGNIFICANCE; CARDIOVASCULAR RISK; METABOLIC SYNDROME; HEART-RATE; DIABETES-MELLITUS; EUROPEAN PANEL; WEIGHT-LOSS;
D O I：
10.2174/157016111401151126161741
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
引用
收藏
页码：76 / 79
页数：4
相关论文
共 59 条
[1]  
Alani Hudaifa, 2014, World J Nephrol, V3, P156, DOI 10.5527/wjn.v3.i4.156
[2]   Harmonizing the Metabolic Syndrome A Joint Interim Statement of the International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; and International Association for the Study of Obesity [J].
Alberti, K. G. M. M. ;
Eckel, Robert H. ;
Grundy, Scott M. ;
Zimmet, Paul Z. ;
Cleeman, James I. ;
Donato, Karen A. ;
Fruchart, Jean-Charles ;
James, W. Philip T. ;
Loria, Catherine M. ;
Smith, Sidney C., Jr. .
CIRCULATION, 2009, 120 (16) :1640-1645
[3]   Combination phentermine and topiramate extended release in the management of obesity [J].
Alfaris, Nasreen ;
Minnick, Alyssa M. ;
Hopkins, Christina M. ;
Berkowitz, Robert I. ;
Wadden, Thomas A. .
EXPERT OPINION ON PHARMACOTHERAPY, 2015, 16 (08) :1263-1274
[4]   Diagnosis and Classification of Diabetes Mellitus [J].
DIABETES CARE, 2010, 33 :S62-S69
[5]   Effect of liraglutide administration and a calorie-restricted diet on lipoprotein profile in overweight/obese persons with prediabetes [J].
Ariel, D. ;
Kim, S. H. ;
Abbasi, F. ;
Lamendola, C. A. ;
Liu, A. ;
Reaven, G. M. .
NUTRITION METABOLISM AND CARDIOVASCULAR DISEASES, 2014, 24 (12) :1317-1322
[6]   Safety and efficacy of liraglutide in patients with type 2 diabetes and elevated liver enzymes: individual patient data meta-analysis of the LEAD program [J].
Armstrong, M. J. ;
Houlihan, D. D. ;
Rowe, I. A. ;
Clausen, W. H. O. ;
Elbrond, B. ;
Gough, S. C. L. ;
Tomlinson, J. W. ;
Newsome, P. N. .
ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2013, 37 (02) :234-242
[7]   Cardiovascular risk across the histological spectrum and the clinical manifestations of non-alcoholic fatty liver disease: an update [J].
Athyros, Vasilios G. ;
Tziomalos, Konstantinos ;
Katsiki, Niki ;
Doumas, Michael ;
Karagiannis, Asterios ;
Mikhailidis, Dimitri P. .
WORLD JOURNAL OF GASTROENTEROLOGY, 2015, 21 (22) :6820-6834
[8]   Are statins 'IDEAL' for non-alcoholic fatty liver disease? [J].
Athyros, Vasilios G. ;
Katsiki, Niki ;
Karagiannis, Asterios ;
Mikhailidis, Dimitri P. .
CURRENT MEDICAL RESEARCH AND OPINION, 2014, 30 (02) :229-231
[9]   Nonalcoholic Fatty Liver Disease and Severity of Cardiovascular Disease Manifestations [J].
Athyros, Vasilios G. ;
Katsiki, Niki ;
Karagiannis, Asterios .
ANGIOLOGY, 2013, 64 (08) :572-575
[10]  
Athyros VG, 2012, CURR VASC PHARMACOL, V10, P374
123456